Navigation Links
Watson to Present at the 2012 Bank of America Merrill Lynch Global Healthcare Conference
Date:8/29/2012

PARSIPPANY, N.J., Aug. 29, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 Bank of America Merrill Lynch Global Healthcare Conference on Wednesday, September 12, 2012 at 10:25AM Eastern Time (3:25PM London Time) at Merrill Lynch Financial Center in London. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  The webcast can also be accessed at the following URL:

http://www.media-server.com/m/p/8qogd5t2

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology.  Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
2. Watson to Acquire Actavis Group for EUR4.25 Billion
3. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
4. Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
5. Watson Confirms Lo Loestrin® Fe Patent Challenge
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. Watson Confirms Testim® Patent Challenge
8. Watson to Present at the Jefferies 2012 Global Healthcare Conference
9. Watson Announces Lidoderm® Patent Challenge Settlement
10. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
11. Watson to Host Second Quarter 2012 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International Myeloma ... myeloma patients while working toward prevention and a cure ... for introducing a federal resolution (H. Res. 174) that ... as "National Multiple Myeloma Awareness Month." Currently ... worldwide, and more than 110,000 new cases are diagnosed ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... Nov. 4 CVS Caremark (NYSE: CVS ) ... position of SVP, Marketing for its pharmacy benefit management ... marketing from Jack Bruner, who is transitioning to the ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings ...
... 4 Neuronascent, Inc., a privately-held biotechnology company ... of depression, Alzheimer,s disease, Parkinson,s and other neurodegenerative ... agreement with ChemRar Pharma, a Russian biotechnology start-up ... and stem cells to treat cancer. Under the ...
Cached Medicine Technology:Company Appoints New SVP, Marketing for PBM Business 2Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform 2
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Emergency Medical ... urgent care in Manhattan, recently commemorated its three-year anniversary ... in Manhattan. In addition to 24-hour urgent care, Emergency ... , At this time, Emergency Medical Care’s ... pain, asthma, chest pain, eye injuries, ear infections, fevers, ...
(Date:3/28/2015)... IL (PRWEB) March 28, 2015 Centurion Service ... equipment auction on Thursday, April 2 at their Las Vegas ... Vegas, NV 89081. The sale, which consists of equipment from ... begin promptly at 9 a.m. PDT. , Buyers will ... and surgery equipment. “We are a one-stop-shop,” said Erik Tivin, ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... injuries is a growing field in orthopaedic medicine. While ... labral tear to confirm the pain etiology, research presented ... ( AOSSM ) Specialty Day suggests that pain relief ... following arthroscopic hip surgery. , “Our study looked ...
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... the $60 billion international beauty products industry is ... a hundred cosmetics are in the Project on ... manufacturers as containing nanomaterials. , Critical to ... in their safety. In Europe, regulators and companies ...
... The rate of childhood,obesity in America has ... percent of children ages 10 to 17 are ... threat of the obesity epidemic for,children, families, communities ... a Healthy Florida ( http://www.bluefoundationfl.com ), the,philanthropic affiliate ...
... Joins 40 Others in Screening for Life-Threatening, Genetic,Disease, ... and the District of Columbia in requiring that all ... congratulate Alabama for initiating a newborn screening program for,cystic ... of the,Cystic Fibrosis Foundation. "More than 40 states are ...
... the Number of Women,s ... Medications Offered at a Discount, CINCINNATI, May 13 ... will expand their generic drug,program -- offering customers lower prices ... is offering 90-day prescriptions for,only $10 on its expanded generic ...
... Ancient acupuncture and modern myofascial pain therapy each focus ... treat pain, although they do it differently, says a ... two techniques. , Results of the study, published May ... suggest that people who want relief from chronic musculoskeletal ...
... New Retinoic Acid and Clindamycin Products Developed ... Skinvisible, Inc. (OTC,Bulletin Board: SKVI) ( ... on formulating enhanced patented dermatology,products, announced it ... Pharmaceutical Co. Ltd. ("Embil"). The Agreement is ...
Cached Medicine News:Health News:The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity 2Health News:Alabama Begins Mandatory Screening of Newborns for Cystic Fibrosis 2Health News:Kroger and Its Family of Stores Expand Discounted Generic Drug Program 2Health News:Kroger and Its Family of Stores Expand Discounted Generic Drug Program 3Health News:Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas 2Health News:Skinvisible Signs Licensing Agreement for Two Acne Formulations 2Health News:Skinvisible Signs Licensing Agreement for Two Acne Formulations 3
... Analyzer II is a ... to enumerate fluorescently labeled ... selected and aligned. The ... CellTracks® Analyzer II, a ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: